Physician profile
Avinash Narine
NPI 1235427030
$5,488.41
in general payments reported to CMS, 2019-2025
38 companies · $1,092 in 2025
The $1,092 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $423 · 2020: $73.99 · 2021: $429 · 2022: $1,281 · 2023: $1,256 · 2024: $933 · 2025: $1,092.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,281.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $762.47 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $666.16 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $590.24 | 2019-2025 | Mounjaro, Zepbound |
| Mylan Specialty L.P. | $390.41 | 2021-2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $286.00 | 2021-2024 | |
| Amgen INC. | $268.76 | 2019-2024 | Repatha, Otezla |
| Corcept Therapeutics | $255.89 | 2024-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $252.78 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $231.94 | 2019-2024 | |
| Abbvie INC. | $208.94 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $183.49 | 2019-2024 | Belsomra |
| Exact Sciences Corporation | $146.77 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $141.02 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.53 | 2021-2023 | Jardiance, Synjardy, Ofev |
| Inspire Medical Systems, INC. | $108.44 | 2023-2025 | Inspire |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $96.39 | 2024-2025 | |
| Abiomed | $94.79 | 2025 | |
| Neurocrine Biosciences, INC. | $79.82 | 2025 | |
| Sanofi-Aventis U.S. LLC | $66.76 | 2024-2025 | |
| Edwards Lifesciences Corporation | $63.57 | 2022-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abbott Laboratories | $59.12 | 2023-2025 | Freestyle Libre 3, Proclaim |
| Allergan, INC. | $48.96 | 2019 | |
| Amarin Pharma, INC. | $34.23 | 2022 | |
| Viatris Specialty LLC | $32.00 | 2025 | Yupelri |
| Madrigal Pharmaceuticals | $30.00 | 2025 | Rezdiffra |
| Medtronic, INC. | $29.09 | 2023 | Intellis Adaptivestim |
| Astellas Pharma US INC | $28.23 | 2023-2024 | Veozah, Myrbetriq |
| Actelion Pharmaceuticals US, INC. | $28.16 | 2023 | Uptravi, Opsumit |
| Ultragenyx Pharmaceutical INC. | $23.32 | 2024 | Crysvita |
| Sunovion Pharmaceuticals INC. | $23.04 | 2019 | |
| Novartis Pharmaceuticals Corporation | $22.12 | 2021 | |
| Hikma Pharmaceuticals USA | $20.24 | 2022 | |
| Bavarian Nordic A/S | $17.81 | 2025 | Vivotif |
| Mannkind Corporation | $15.90 | 2020 | |
| Xeris Pharmaceuticals, INC. | $15.34 | 2025 | Gvoke Hypopen |
| United Therapeutics Corporation | $15.21 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.82 | 2019 | |
| Dexcom, INC. | $13.65 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avinash Narine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.